Pharmacogenomics in the Treatment of Alzheimer's Disease investigates genetic factors influencing responses to Alzheimer's therapies. It covers genetic markers that predict efficacy and adverse effects of drugs like cholinesterase inhibitors and NMDA receptor antagonists. The book emphasizes personalized treatment plans to enhance cognitive outcomes and minimize side effects in Alzheimer's patients. Ideal for neurologists and pharmacogenomic researchers, it advances precision medicine in neurodegenerative disease management.
Zachary Crawford integrates pharmacogenomics into the treatment of Alzheimer's disease-related skin conditions, focusing on managing dermatitis and skin infections in patients with Alzheimer's. His research explores how genetic variations influence responses to medications used in treating skin issues associated with Alzheimer's. Zachary has published extensively on personalizing dermatological treatments for Alzheimer's patients through pharmacogenomic testing to enhance efficacy and minimize side effects. He also provides guidelines for clinicians to utilize pharmacogenomic strategies in managing Alzheimer's-related skin conditions, promoting personalized and effective dermatological care through genetic-informed approaches.